These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 14706898)

  • 1. [Which medico-economic approaches must be taken to evaluate the impact of costly molecules in oncology? The model of Herceptin in the breast metastatic cancer].
    Ganne C; Trillet-Lenoir V; Jaisson-Hot I; Chauvin F; Clippe C; Heilmann MO; Hajri T; Poncet B; Heuclin C; Colin C
    Bull Cancer; 2003 Nov; 90(11):955-60. PubMed ID: 14706898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
    de Lima Lopes G; Gluck S
    J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
    [No Abstract]   [Full Text] [Related]  

  • 4. Roche responds to the 'Herceptin or deception' article.
    Petersen S
    N Z Med J; 2006 Jul; 119(1237):U2069; author reply U2069. PubMed ID: 16862210
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
    Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
    Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
    Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
    Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
    Rosevear M
    N Z Med J; 2006 Jun; 119(1235):U2014. PubMed ID: 16751832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

  • 10. Oh, Canada: Public outcry pushed demand for trastuzumab for early-stage breast cancer.
    Smith M
    J Natl Cancer Inst; 2005 Sep; 97(18):1327. PubMed ID: 16174852
    [No Abstract]   [Full Text] [Related]  

  • 11. PHARMAC responds on Herceptin assumptions and decisions.
    Metcalfe S; Evans J
    N Z Med J; 2007 Aug; 120(1260):U2692. PubMed ID: 17726504
    [No Abstract]   [Full Text] [Related]  

  • 12. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
    Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203
    [No Abstract]   [Full Text] [Related]  

  • 13. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan.
    Kondo M; Toi M
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):197-204. PubMed ID: 16445372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.
    Norum J
    Expert Opin Pharmacother; 2006 Aug; 7(12):1617-25. PubMed ID: 16872264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact analysis of trastuzumab in early breast cancer: a hospital district perspective.
    Purmonen TT; Auvinen PK; Martikainen JA
    Int J Technol Assess Health Care; 2010 Apr; 26(2):163-9. PubMed ID: 20392319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital.
    Neyt MJ; Albrecht JA; Clarysse B; Cocquyt VF
    Int J Technol Assess Health Care; 2005; 21(1):132-7. PubMed ID: 15736525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Herceptin therapy in breast cancer: new indication?].
    Lebeau A
    Verh Dtsch Ges Pathol; 2006; 90():99-106. PubMed ID: 17867585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer].
    Huober J; Jackisch C; Untch M; Möbus V; Wallwiener D; Kaufmann M; Minkwitz G
    Zentralbl Gynakol; 2006 Feb; 128(1):30-7. PubMed ID: 16450285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.